Telix Pharmaceuticals (TLX) reported $804M in revenue for fiscal 2025, +55.6% year on year. That ranks #1917 by revenue among 2853 SEC filers and #180 in Healthcare. It posted a net loss of −$7.1M for the same year. Revenue has grown 55.4% a year on average since 2023 ($333M then). The fiscal 2025 balance sheet shows $1.2B in total assets, $142M in cash and $392M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenue | $804M | +55.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $426M | +26.9% | FY20252025-12-31 |
| Operating incomeProfitLossFromOperatingActivities | $29.8M | −46.0% | FY20252025-12-31 |
| Net incomeProfitLossAttributableToOwnersOfParent | −$7.1M | −$40.8M | FY20252025-12-31 |
| Operating cash flowCashFlowsFromUsedInOperatingActivities | −$17.3M | −$44.8M | FY20252025-12-31 |
| Capital expenditurePurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | $25.7M | +181.8% | FY20252025-12-31 |
| Total assetsAssets | $1.2B | +23.8% | FY20252025-12-31 |
| Shareholders' equityEquity | $415M | +17.7% | FY20252025-12-31 |
| CashCashAndCashEquivalents | $142M | −67.8% | FY20252025-12-31 |
| Long-term debtLongtermBorrowings | $392M | +14.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Figures are reported under IFRS, in US dollars.
Profile
- Legal name
- Telix Pharmaceuticals Ltd
- Ticker
- TLX
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0002007191
Filings
- 20-FFeb 20, 2026Open filing →
- 20-FFeb 24, 2025Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Orthofix MedicalOFIX | $822M | −$92.2M |
| Ascendis PharmaASND | $814M | −$258M |
| Caris Life SciencesCAI | $812M | −$68.1M |
| Telix PharmaceuticalsTLX | $804M | −$7.1M |
| U S Physical TherapyUSPH | $781M | $39.6M |
| Collegium PharmaceuticalCOLL | $781M | $63.0M |
| Alphatec HoldingsATEC | $764M | −$143M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Telix Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/telix-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Telix Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/telix-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-telix-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Telix Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/telix-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001628280-26-009943 · February 20, 2026
{{cite web |title=Telix Pharmaceuticals — Key figures — 20-F (0001628280-26-009943) |url=https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-20}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.